Teniposide for Acute Lymphoblastic Leukemia
Teniposide (ten i poe' side; VM 26; Vumon - Bristol), an anticancer drug that has been under investigation in the USA for 20 years, has now been approved for use in combination induction treatment of refractory acute lymphoblastic leukemia (ALL) in children. A semisynthetic derivative of podophyllotoxin, teniposide is chemically related to etoposide (VePesid - Medical Letter, 26:48, 1984)....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Teniposide for Acute Lymphoblastic Leukemia
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 883
Article Code: 883b
Date: November 13, 1992
Volume: 34
Pages: 105-106
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 883
Article Code: 883b
Date: November 13, 1992
Volume: 34
Pages: 105-106
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)